Princeton’s West Innovation Campus will soon house a new medical manufacturing site and clinical research and development center.
BeiGene, Ltd., a biotechnology company focused on developing and commercializing cancer medicines, has purchased a 17 ha (42 acre) site on the university’s campus in Hopewell, New Jersey.
BeiGene expects to invest several hundred million dollars in the initial phase of construction, in addition to the acquisition of the property. The state-of-the-art facility is expected to include up to 37,161 m2 (400,000 sf) of commercial-stage biologic pharmaceutical manufacturing—including up to 16,000 L (4227 gal) of biologics capacity—along with research and development and office space.
Construction of the initial phase is expected to commence in 2022 and be completed in 2023 or 2024. The property has more than 92,903 m2 (one million sf) of useable real estate for future expansion.
BeiGene acquired the Hopewell property from Lincoln Equities Group. It has retained DPR Construction as its construction management firm and IPS as its architectural and engineering firm.
“With more new companies, like BeiGene, coming into the Princeton West Innovation Campus, Hopewell Township’s future as a leader in the biotech base continues to come to fruition. BeiGene’s expertise in developing innovative cancer treatments combined with their planned state-of-the-art facility makes this a win-win for Hopewell, BeiGene, and the millions of cancer patients whose lives will hopefully improve from BeiGene medicines. We are proud that those medicines will be manufactured right here,” said Hopewell Township’s mayor, Julie Blake.
Responses